Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADIANCE-NK: TROP2 CAR/IL-15 TGFBR2 KO NK Cells in Advanced Head and Neck Cancer
NCT07101432Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of TROP2 CAR/IL-15 TGFBR2 KO NK cells in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and Adverse Events (AEs) at 1 year. Started Dec 2025; status: recruiting.
02
Drugs
TROP2 CAR/IL-15 TGFBR2 KO NK cells
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07101432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07101432.